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Abstract
Background: Alcohol dependence is a significant issue contributing to disease burden. Changes in cortisol
concentrations during alcohol withdrawal are associated with cognitive deficits and symptoms of depression.
Current treatments are only successful for a small proportion of people and do not target cognitive deficits and
symptoms of depression experienced by those who are alcohol dependent. The aim of this research is to
determine the potential efficacy of mifepristone, a type II glucocorticoid receptor antagonist, to prevent symptoms
of depression and cognitive deficits following alcohol detoxification.
Methods: This was a phase 2 therapeutic use trial. It was a double-blind randomised controlled clinical trial of
mifepristone versus inactive placebo treatment. The trial aimed to recruit 120 participants who met the inclusion
criteria: (1) male, (2) aged 18–60 years inclusive, and (3) alcohol dependent for 5 or more years. Participants were
randomised to 600 mg a day mifepristone (200 mg morning, afternoon, and evening) for 7 days and 400 mg for the
subsequent 7 days (200 mg morning and evening) or the equivalent number of placebo tablets for 14 days. Primary
outcome measures were cognitive function (measured using the Cambridge Neuropsychological Test Automated
Battery (CANTAB)) and symptoms of depression (measured using the Beck Depression Inventory (BDI)) at 4 weeks
post-randomisation.
Results: Difficulties recruiting participants due to significant changes in the provision of inpatient care for alcohol
dependence resulted in only 27 participants recruited to the trial, with data available for 21 participants. Fourteen
participants were randomised to receive mifepristone and 13 to receive placebo.
Conclusion: Larger trials would be needed to draw conclusions about the efficacy of mifepristone.
Trial registration: ISRCTN registry ISRCTN54001953. Registered on 29 September 2011.
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Background
Alcohol dependence is a significant global problem con-
tributing to over 4% of disease burden [1], impacting so-
cial, physical, and mental health. Pharmacological and
psychosocial treatments for alcohol dependence are only
successful for a subsample of people, with up to 70%
returning to drinking within the first 12 months follow-
ing treatment [2]. Recurrent episodes of drinking and
withdrawal result in the phenomenon of kindling, with
greater severity of withdrawal symptoms including risk
of seizure [3] and greater cognitive deficits [4]. New, ef-
fective treatments are therefore required to help reduce
rates of relapse and the health, social, and economic
consequences of multiple episodes of dependent drink-
ing and withdrawal.
Impairment in cognitive function is found in 50 to
80% of those dependent on alcohol with impairment ex-
perienced across multiple domains including memory,
attention, learning, processing speed, visuospatial abil-
ities, and executive function [5, 6]. These impairments
may hinder an individual’s quality of life and their ability
to benefit from treatment programmes [7–11]. In
addition to cognitive deficits, those with a diagnosis of
alcohol dependence are two times more likely to be di-
agnosed with major depression [12]. Greenfield et al.
[13] found that those entering inpatient treatment for al-
cohol dependence who also had a diagnosis of major de-
pression had a shorter time to first drink and relapse in
the first year following treatment.
Alcohol withdrawal-induced abnormalities of the
hypothalamic-pituitary-adrenal (HPA) axis function have
been associated with both deficits in memory and symp-
toms of depression [14–16]. High levels of glucocorti-
coids are released during acute withdrawal from alcohol,
and these may have a causative role in the exacerbation
of cognitive deficits [17] and persistent glucocorticoid
dysregulation following abstinence from alcohol may re-
sult in sustained cognitive dysfunction [18]. Further-
more, Errico et al. [19] demonstrated a link between
severity of cognitive deficits and the number of with-
drawal episodes and higher cortisol levels during acute
alcohol withdrawal. Clinical research has demonstrated
that a type II glucocorticoid receptor antagonist, mife-
pristone, has a positive impact on symptoms of depres-
sion [20–24] and cognitive function [25].
In preclinical studies, administration of mifepristone early
in the acute phase of alcohol withdrawal reduced neuronal
toxicity and deficits in cognitive function [26–28]. Sharrett-
Field et al. [29] demonstrated that this drug significantly re-
duced the signs of alcohol withdrawal. Reynolds et al. [30]
demonstrated that another type II glucocorticoid antagon-
ist, ORG 34517, reduced the severity of alcohol withdrawal
in rats. It was therefore hypothesised that blocking type II
glucocorticoid receptors during acute withdrawal could
reduce the deficits in cognitive function and symptoms of
depression in alcohol dependence. Current pharmacological
treatment for alcohol dependence targets alcohol consump-
tion directly and does not tackle the cognitive deficits and
symptoms of depression that are experienced following al-
cohol withdrawal. The current study (MifCog) is the first
published report of an investigation examining the potential
efficacy of mifepristone given to alcohol-dependent persons
during acute alcohol withdrawal to protect against subse-
quent deficits in cognitive function and symptoms of
depression.
Method
This research aimed to determine the potential efficacy
of mifepristone for preventing symptoms of depression
and cognitive deficits following alcohol detoxification. It
was hypothesised that mifepristone would be associated
with greater cognitive function and fewer symptoms of
depression in comparison to placebo.
Participants
Full details of the trial methodology and design are re-
ported in Donoghue et al. [31]. Participants were male
(given mifepristone’s antiprogestogen effects, it is unsuit-
able for female administration), aged between 18 and 60
years old with a diagnosis of alcohol dependence for at
least 5 years (determined using the Composite Inter-
national Diagnostic Interview (CIDI) [32]) and scheduled
to complete an alcohol detoxification. Exclusion criteria
included the following: a clinical diagnosis of a neuroen-
docrine disorder, liver damage (alanine aminotransferase
(ALT) activity of more than 2.5× normal range), renal
dysfunction (creatinine levels over 150 μmol/l in
plasma), documented evidence of a psychotic disorder,
severe brain damage or severe mental impairment, a
diagnosis of severe physical illness that would preclude
participation (e.g. terminal illness), documented evidence
of current dependence on a substance other than alcohol
or nicotine, inability to understand sufficient English to
understand the information needed for the cognitive
testing, patients with Wernicke-Korsakoff syndromes,
porphyria, severe asthma uncontrolled by therapy, a car-
diac disorder, persistent high blood pressure (over 160
mmHg systolic and/or 100 mmHg diastolic), a medical
history of diabetes, a known allergy to mifepristone, pre-
scription of contraindicated medications, and current
participation in another clinical trial.
Participants were identified through community drug
and alcohol teams in South East London, Kent, Sussex,
Barnsley, and Hull in England. All potential participants
were given written and verbal information about the trial
before written informed consent was obtained. Medical
history was determined by a trained physician through
full history, case note, and medication review. Ethical
Donoghue et al. Trials          (2020) 21:796 Page 2 of 9
approval was granted by the London–Dulwich Research
Ethics Committee (reference: 10/H0808/7) and complies
with UK and European Good Clinical Practice for medi-
cinal trials guidelines.
Primary outcomes
The primary outcomes of this research were depression in
the first 4weeks following initiation of detoxification and
cognitive function. Symptoms of depression were assessed
on days 7, 14, 21, and 28 using the BDI. Assessment of cog-
nitive function was completed using the Cambridge Auto-
mated Test Battery (CANTAB [33]) on days 21 and 28.
Specific CANTAB tests were chosen to assess a wide range
of domains of cognitive function known to be affected by
dependent drinking, which included the following: Motor
Screening task that checks for movement and visual prob-
lems; Reaction Time task that measures motor skill function;
Pattern Recognition Memory; Matching to Sample Visual
Search that measures visual matching ability and short-term
visual recognition memory; Spatial Recognition Memory;
Paired Associates Learning that measures visual memory
and new learning; Rapid Visual Information Processing that
measures sustained attention; Intra-Extra Dimensional Set
Shifting that measures attentional set formation mainten-
ance, shifting, and flexibility; Spatial Working Memory; and
One Touch Stockings of Cambridge that measures planning
and working memory subdomains of executive function.
Cognitive testing did not take place at the initial baseline as-
sessment due to participants being intoxicated; this would
have had a significant impact on ability to perform the tests.
Secondary outcomes
Secondary outcomes collected on days 7, 14, 21 and 28
included the Profile of Mood States (POMS [34]),
Snaith-Hamilton Pleasure Scale (SHAPS [35]), previous
night’s sleep quality (on a scale of 1–10, with 10 being
the best night sleep), and the Alcohol Urge Question-
naire (AUQ [36]). A cut-off score of 2 was used to indi-
cate possible anhedonia on the SHAPS [35]. Urine
samples were taken just prior to the cognitive testing on
days 21 and 28 after cessation of alcohol drinking to es-
tablish the concentrations of the unhydrolysed levels of
chlordiazepoxide and the active metabolites norchlordia-
zepxide (also known as desmethylchlordiazepoxide), ox-
azepam, demoxepam, and nordiazepam (also known as
desmethyldiazepam) [37, 38]. During the initial 4 weeks
of the trial, all participants were asked to report any ad-
verse events at each research visit.
Design and procedure
The study was designed as a double-blind, parallel-
group, randomised controlled clinical trial of mifepris-
tone and inactive placebo. It is a phase 2 therapeutic use
trial. A baseline assessment was completed a maximum
of 4 weeks prior to detoxification to determine eligibility
for the trial and to collect data on participant demo-
graphics, alcohol consumption (Timeline Follow-back
(TLFB) [39], Severity of Alcohol Dependence Question-
naire (SADQ) [40], Alcohol Urge Questionnaire (AUQ)
[36]), and symptoms of depression (Beck Depression In-
ventory (BDI) [41]), see Table 1.
On the first day of detoxification, participants were
randomised 1:1 to receive mifepristone or placebo. Ran-
domisation was performed using an online system sup-
ported by King’s Clinical Trials Unit at the Institute of
Psychiatry, Psychology and Neuroscience. Allocation was
stratified by severity of alcohol dependence (SADQ score
of 40 or more or under 40), research site, and age (18 to
29, 30 to 39, 40 to 49, or 50 to 60). All participants, clin-
ical staff, and research staff were blind to medication
Table 1 Participant demographics, drinking-related variables, and depression symptoms at baseline for those randomised and those
not randomised
Randomised (n = 27) Mifepristone (n = 14) Placebo (n = 13) Not randomised (n = 30)
Age, mean (SE) 41.9 (1.6) 42.9 (2.4) 40.8 (2.1) 45.3 (1.7)
White, n (%) 26 (96.3) 13 (92.9) 13 (100.0) 18 (85.7)
Married or cohabiting, n (%) 2 (7.4) 0 (0.0) 2 (15.4) 1 (4.8)
In employment, n (%) 1 (3.7) 0 (0.0) 1 (7.7) 2 (9.5)
Professional or skilled, n (%) 9 (33.3) 3 (21.4) 6 (46.2) 10 (47.6)
Home owner, n (%) 1 (3.7) 1 (7.1) 0 (0.0) 0 (0.0)
Years of education, mean (SE) 11.1 (0.5) 12.1 (0.6) 10.6 (0.3) 13.1 (0.9)
Number of children, mean (SE) 2.2 (0.3) 2.7 (0.4) 1.9 (0.5) 2.4 (0.3)
Age of first drink, mean (SE) 12.5 (0.5) 13.6 (0.7) 12.6 (0.7) 14.2 (0.5)
Age drinking weekly, mean (SE) 16.4 (0.7) 17.1 (0.7) 17.1 (1.1) 20.0 (2.1)
Age drinking daily, mean (SE) 24.6 (2.7) 26.9 (2.9) 21.4 (1.2) 25.8 (2.81)
Beck Depression Inventory, median (IQR) 33 (13) 32 (9.5) 40 (24.5) 36 (14.5)1
1Data available for 16 participants
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allocation. All tablets were identical, stored in blister packs
in cartons labelled with unique ID numbers, which were al-
located to participants following randomisation. Partici-
pants were administered 200mg of mifepristone or placebo
three times a day (morning, afternoon, evening) for 7 days,
starting as soon as possible on the first day of detoxification.
This was followed by 200mg of mifepristone or placebo
twice a day (morning and evening) for 7 days.
Protocol changes
Many potential participants were being excluded from
participation in the trial due to a diagnosis of asthma.
Clarification of the exclusion criteria for those suffering
from asthma was made to exclude only those with severe
asthma uncontrolled by therapy. Due to the changes in
service provision for the treatment of alcohol dependence
and new available research with mifepristone, patients
completing their alcohol detoxification as an outpatient
were included in the trial. Due to research grant funding
limitations, this only included one participant.
Medication adherence
Supervised dosing of mifepristone/placebo was com-
pleted for all participants completing their detoxification
as an inpatient for the entire 2-week course of the medi-
cation. Those completing their detoxification as an out-
patient were asked to record each dose of medication.
Follow-up assessments
Participants were followed up at 3, 6, and 12 months post-
randomisation to assess levels of alcohol consumption
(TLFB) and problems associated with alcohol consumption
(APQ; 6 and 12months only), and symptoms of depression,
alcohol craving, mood, and anhedonia were collected using
the BDI, AUQ, POMS, and SHAPS, respectively.
Sample size
Previous data on this target population was not avail-
able to establish how many participants would be re-
quired. However, previously published studies using the
CANTAB test battery in depressed patients have shown
effect sizes of 0.5, 0.8, 0.76 [42], 0.496, 0.5 [43], 0.897
[44], and, in the aged, 0.7 for spatial working memory
[45]. Similar values were obtained studying effects of
acute alcohol with an early version of the CANTAB
[46]. We estimated the numbers needed in each group
for a variety of effect size estimates based on a power of
80% and alpha of 0.05. For an effect size difference of
0.8 25, subjects per group would be required and this
increased to 32 for an effect size difference of 0.7 and
63 if the difference was 0.5. We erred on the side of
caution and aimed to detect a small to medium effect
size of 0.5, and this required 120 subjects participating
in the study, 60 in each group.
Data analysis
Due to under-recruitment of participants, the trial was
inadequately powered to perform inferential statistics.
Outcomes are therefore presented as means with stand-
ard errors (SE) or standard deviations (SD) or medians
with interquartile ranges, as appropriate. Mean differ-
ences are reported with 95% confidence intervals (CI).
Results
Study population and recruitment difficulties
Recruitment for the trial began in September 2012, and
the final participant follow-up assessment took place in
July 2016. A total of 57 people were screened to take
part in the trial, and 27 (47%) were randomised (Fig. 1);
Table 1 presents the demographics of these. Similar
levels of alcohol consumption, alcohol problems, and
craving were apparent for those who were allocated pla-
cebo and those who were allocated mifepristone
(Table 2). A total of 6 participants withdrew from the
trial. Three participants randomised to placebo and two
participants randomised to mifepristone withdrew con-
sent owing to terminating their alcohol detoxification
and before completion of the trial primary outcome
measures. Withdrawal of participants prior to the ad-
ministration of the primary outcomes resulted in re-
moval of the data for that participant from the study
results as per the trial protocol.
One participant randomised to mifepristone was with-
drawn from the trial due to the necessity of treatment
with a contraindicated medication. Primary outcome
measures were completed for 21 participants.
The study took place at a time of significant policy
change in the provision of alcohol services in UK. Com-
missioners of alcohol services frequently reviewed ser-
vices and invited new tenders to provide treatment
services contracts (i.e. retendering). As a result, there
were closures of NHS specialist inpatient detoxification
facilities at the participating research sites which pro-
vided serious challenges to recruitment, detailed further
in the “Discussion” section. The original protocol in-
cluded only participants who were completing an alcohol
detoxification as inpatients. A protocol amendment was
made in November 2014 to include participants complet-
ing their alcohol detoxification as an outpatient to expand
the potential participant pool. However, due to further
retendering of alcohol services and funding constraints,
the improvement in recruitment was minimal with only
one participant recruited as an outpatient.
Primary outcomes
At 4 weeks post-randomisation, those who received
mifepristone had a numerically higher mean BDI score
(n = 11, mean = 13.77, SE = 2.36) compared to those who
received placebo (n = 10, mean = 8.50, SE = 2.75) with a
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mean difference of 5.27 (CI = − 2.86 to 13.40). Table 3
presents the mean (SD) for tests of cognitive function at
4 weeks post-randomisation as well as the mean differ-
ence (with 95% confidence intervals) between those re-
ceiving mifepristone and those receiving placebo for
these scores. A numerically higher score indicates super-
ior performance on the Pattern Recognition Memory,
Spatial Recognition Memory, Stockings of Cambridge,
and Match to Sample Visual Search tasks, whereas a
lower score indicates better performance on all other
tasks. Those randomised to receive mifepristone per-
formed better than those randomised to placebo on all
tasks of memory (Paired Associate Learning, Pattern
Recognition Memory, and Spatial Recognition Memory).
However, those randomised to receive placebo per-
formed better than those randomised to receive mife-
pristone on all tasks of executive function (Stockings of
Cambridge, Intra-Extra Dimensional Set Shift, and
Spatial Working Memory tasks) and all tasks of attention
and psychomotor speed (Reaction Time, Rapid Visual
Information Processing, Match to Sample Visual
Search).
Secondary outcomes
Descriptive statistics are reported for the POMS, SHAP
S, AUQ, and sleep quality and are presented in supple-
mentary table 1.
Fig. 1 Trial consort diagram
Table 2 Baseline alcohol consumption characteristics for mifepristone and placebo groups
Mifepristone (n = 14), median (IQR) Placebo (n = 13), median (IQR)
Timeline Follow-back, drinks per drinking day 29.5 (18.1) 27.24 (24.3)
Alcohol Problems Questionnaire 13.5 (6.78) 13.0 (6.5)
Alcohol Urge Questionnaire 47.5 (16.78) 51.0 (31.5)
Drink = 1 UK unit equivalent to 8 g/10 ml of pure ethanol
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Follow-up
Descriptive statistics for outcomes at 3-, 6-, and 12-month
follow-up are presented in supplementary table 2.
Adverse events and medication adherence
No participants withdrew from the trial due to medication
side effects. One participant randomised to receive pla-
cebo experienced a serious adverse event during the trial
that was unrelated to the trial medication. There were 54
reported adverse events during the trial (23 placebo, 31
mifepristone); the most common were headache (4 pla-
cebo, 4 mifepristone), sickness and nausea (3 placebo, 1
mifepristone), and skin rash and itching (1 placebo, 3
mifepristone). Medication adherence was high with 18 of
the 21 participants who completed the 4 weeks of the trial
taking 100% of medication; two participants missed one
dose and one participant missed two doses of medication.
Discussion
This was the first RCT aimed to determine the effective-
ness of mifepristone in reducing the cognitive deficits
and depression symptoms often observed during alcohol
detoxification. Due to significant recruitment challenges,
analysis only involved 27 participants who met eligibility
and were randomised to mifepristone (52%) and placebo
(48%). Therefore, no definitive conclusions could be
drawn. However, it is worth noting that those who re-
ceived mifepristone had greater BDI scores at 4 weeks
post-randomisation compared to those who received
placebo (mean difference = 5.27), indicating greater se-
verity of depression, which may be considered clinically
significant [47]. Those randomised to receive mifepris-
tone had scores indicating superior performance on all
tasks of memory; however, the opposite was true for all
tasks of executive function and attention and psycho-
motor speed.
Five participants were lost from the trial due to them
deciding to discontinue their alcohol detoxification, three
had received placebo and two mifepristone, and the sixth
because of a contraindicated medication. There were no
reported serious side effects related to mifepristone treat-
ment. Compliance was excellent due to medication being
administered by medical staff on the inpatient ward for all
but one study participant. Three treatment doses in total
were missed throughout the study.
Low participant recruitment rates
It did not prove possible to recruit the number of partic-
ipants originally aimed for in this study. This was pri-
marily because of repeated recruitment delays due to
substantial changes in UK addiction services treatment
provision based on new government policy, which is es-
timated to have resulted in a 44.6% reduction in the
number of inpatient treatment admissions over the
course of the study [48]. When the trial was started,
there were two local inpatient detoxification wards that
would have provided many potential participants. These
wards were both closed just as the study began. The
team then moved to recruiting from other NHS special-
ist addiction units at participating research sites, with
each new centre necessitating substantial paperwork be-
fore recruitment could begin. Eight new recruitment
centres were established, but four of these were then
also lost owing to closures or retendering. In addition,
some addiction units changed to only 2 weeks’ inpatient
treatment, instead of the 4 weeks that the original wards
provided and that the trial protocol required. The trial
protocol was amended to allow participants only receiv-
ing 2 weeks of inpatient care to take part. As described
Table 3 Cognitive function at week 4 post-randomisation for mifepristone and placebo groups
Test Mifepristone (n = 11), mean
(SD)





Paired Associates Learning (number of trials) 12.36 (3.47) 12.80 (3.22) − 0.44 (− 3.70 to 2.83)
Pattern Recognition Memory (% correct) 91.67 (7.45) 90.00 (13.49) 1.67 (− 9.18 to 12.51)
Spatial Recognition Memory (% correct) 73.64 (12.86) 66.50 (17.49) 7.14 (− 8.01 to 22.28)
Executive Function
Stockings of Cambridge (number of problems solved) 7.55 (2.54) 8.10 (1.96) − 0.55 (− 2.76 to 1.65)
Intra-Extra Dimensional Set Shift (number of trials) 164.82 (115.87) 117.60 (67.00) 47.22 (− 43.57 to 138.01)
Spatial Working Memory (between errors) 53.09 (17.82) 39.00 (21.20) 14.09 (−5.15 to 33.33)
Attention and psychomotor speed
Reaction Time, reaction (milliseconds) 350.44 (66.57) 330.51 (89.82) 19.92 (− 56.59 to 96.44)
Rapid Visual Information Processing latency
(milliseconds)
473.69 (114.84) 422.68 (134.90) 51.00 (− 75.16 to 177.17)
Match to Sample Visual Search (% correct) 95.96 (5.60) 96.11 (6.44) − 0.16 (− 6.08 to 5.77)
Donoghue et al. Trials          (2020) 21:796 Page 6 of 9
above, the trial protocol was further amended near the
end of the study to include outpatients, but this did not
improve the situation. The study then had to cease be-
cause the repeated delays resulted in expiration of the
funding.
As the study was unable to recruit participant num-
bers, there was insufficient data to show whether or not
mifepristone alleviated or prevented the depressive
symptoms and/or cognitive deficits caused by long-term
alcohol consumption and withdrawal. It was unfortunate
that major changes in government policy on treatment
service provision for alcohol dependence, after the com-
mencement of the study and outside the control of the
researchers, prevented conclusions from being reached.
Study limitations
The sample size for this trial was very small owing to
difficulties recruiting eligible participants as a result of
changes in the inpatient service provision for the treat-
ment of alcohol dependence. Meaningful conclusions
could therefore not be drawn. Only males were included
in this trial due to mifepristone’s blocking effect on pro-
gesterone and the associated risks in women. This limits
the generalisability of the trial findings.
Study strengths
This was the first clinical trial to examine the potential
for mifepristone to prevent cognitive deficits and symp-
toms of depression during alcohol detoxification. This
trial used a double-blind placebo-controlled design.
Future directions
Several preclinical reports have shown that type II receptor
glucocorticoid antagonists could be of value during alcohol
detoxification. Since the current trial was started, Vendrus-
colo et al. [49] published results from a double-blind la-
boratory study in alcohol-dependent volunteers. Compared
with placebo, mifepristone reduced alcohol-cued craving
that has been shown to be predictive of relapse drinking
and reduced self-reported alcohol consumption.
Mifepristone, in addition to its antagonism at type II
glucocorticoid receptors, has progesterone antagonist prop-
erties. In the present study, the latter effect meant that the
participants had all to be males. However, in recent years,
type II receptor antagonists have been developed that do
not possess any progesterone antagonism; ORG34517 is
showing promising results in alcohol dependence.
Recruitment for this trial relied on the provision of
NHS addiction treatment services with potential partici-
pants requiring 2 weeks of inpatient treatment to moni-
tor administration of mifepristone. Due to the changes
in treatment provision for alcohol addiction, recruitment
of suitable participants was extremely problematic, with
few patients receiving NHS inpatient treatment. Future
research could develop a trial protocol that allows for
patients receiving treatment as an outpatient. Careful
consideration would need to be given to ensure the
safety of patients is adequately monitored and adherence
to the medication is maximised. The use of Clinical Re-
search Facilities (CRFs) would provide an alternative
strategy. CRFs can provide a dedicated space with spe-
cialist staff for clinical research. The costs for the use of
such facilities can be considerable so would need to be
considered when applying for research funding.
Conclusion
This research was not able to determine the potential ef-
ficacy of glucocorticoid receptor antagonism for prevent-
ing cognitive deficits and symptoms of depression
following an alcohol detox. Further research is war-
ranted, but careful consideration needs to be given to re-
search protocols that include participants completing an
alcohol detoxification as an outpatient or the use of a
CRF to maximise participant recruitment.
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